Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tetanus vaccine is a biologic preparation used to induce active immunity against tetanus, a severe disease caused by the neurotoxin tetanospasmin produced by *Clostridium tetani*. The vaccine typically consists of tetanus toxoid, which is the bacterial toxin that has been inactivated (usually with formaldehyde) to eliminate toxicity while preserving its ability to stimulate an immune response. The specific investigational product described in the context is an adsorbed tetanus vaccine developed by AIM Vaccine Co., Ltd. (Aimei Vacin BioPharm), which is currently in Phase I clinical trials to evaluate safety and immunogenicity in healthy adults. Adsorption to aluminum salts (alum) is a common formulation strategy used to enhance the vaccine's immunogenicity by acting as an adjuvant.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on tetanus vaccine.